Systemic AL amyloidosis due to non‐Hodgkin's lymphoma: an unusual clinicopathologic association
Open Access
- 12 January 2004
- journal article
- website
- Published by Wiley in British Journal of Haematology
- Vol. 124 (3) , 309-314
Abstract
Summary: Systemic AL amyloidosis (AL) is a disorder in which light chains form fibrillar deposits, leading to organ dysfunction and death. Rarely, AL has been associated with non‐Hodgkin's lymphoma (NHL), although this association has not been well characterized. We report a series of six patients with AL associated with NHL, primarily lymphoplasmacytic lymphoma. Organ involvement was variable, with frequent bulky lymphadenopathy and visceral cavity deposits, but no cardiac involvement. Positron emission tomography scans were negative. Bone marrow and lymph node biopsies showed a mixed population of CD20+ lymphoid and CD138+ plasma cells. Serum free light chains were elevated, and correlated with response to therapy. Immunoglobulin light chain variable region (Ig VL) germline gene use was typical for AL, reflecting previously observed correlations between germline gene use and organ tropism. Five patients received rituximab‐based therapies with two responses. Two patients underwent autologous stem cell transplantation with one complete haematological response. Four patients survive at 10–132 months from diagnosis. AL with NHL has distinctive clinical features but employs the same Ig VL gene repertoire as AL with clonal plasma cell dyscrasias. Serial serum free light chain levels are useful for tracking response to therapy. Treatments aimed at both lymphoid and plasma cell components appear warranted.Keywords
This publication has 23 references indexed in Scilit:
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003
- Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL)Blood, 2003
- Utility of FDG-PET scanning in lymphoma by WHO classificationBlood, 2003
- Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(λIII) as a new amyloid-associated germline gene segmentBlood, 2002
- Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosisJournal of Clinical Pathology, 2001
- The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burdenBlood, 2001
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineNew England Journal of Medicine, 1997
- Lymphadenopathy due to amyloid deposition in non-Hodgkin’s lymphomaAnnals of Oncology, 1997
- Treatment of AL-Amyloidosis with Dexamethasone Plus Alpha InterferonLeukemia & Lymphoma, 1997
- Malignant lymphoma of mucosa associated lymphoid tissue: a new etiology of amyloidosisPathology - Research and Practice, 1995